Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2017
Moves to end veto on health insurance premiums
9 March 2017 - Health insurers are stepping up their campaign to end government veto power over insurance premiums, arguing ...
Posted by Michael Wonder on 07 Mar 2017
What aspects of an economic evaluation are commercially sensitive?
6 March 2017 - Interesting insights from the pCODR Initial Economic Guidance Report for alectinib hydrochloide (Alecensaro). ...
Posted by Michael Wonder on 07 Mar 2017
PBAC publishes final two outcomes from the November 2016 meeting
7 March 2017 - The outcomes for tolvaptan and trifluridine with tipiracil hydrochloride are now available. ...
Posted by Michael Wonder on 07 Mar 2017
Ontario cancer patient 'in limbo' over chemotherapy drug shortage
7 March 2017 - A cancer patient who was told last week that she may not receive her much-needed chemotherapy ...
Posted by Michael Wonder on 07 Mar 2017
Time for public listing of specialist fees
6 March 2017 - Medical specialists should be required to list their fees publicly to ensure patients are able to ...
Posted by Michael Wonder on 07 Mar 2017
Defining the non-inferiority margin and analysing non-inferiority: an overview
6 March 2017 - Non-inferiority trials are used to assess whether the effect of a new drug is not worse than ...
Posted by Michael Wonder on 06 Mar 2017
Women make plea ahead of decision on breast cancer drug Kadcyla
6 March 2017 - A mother campaigning for a life-extending breast cancer drug to be made available on the NHS ...
Posted by Michael Wonder on 06 Mar 2017
CADTH publishes initial recommendations for three medicines for non-small-cell lung cancer
3 March 2016 - The outcome for three medicines, ceritinib (Zykadia), osimertinib mesylate (Tagrisso) and alectinib hydrochloride (Alecensaro), demonstrate the ...
Posted by Michael Wonder on 06 Mar 2017
Patients' medical payments can vary up to 400% among specialists, report finds
6 March 2017 - There is a massive variation in the out-of-pocket payments patients make to medical specialists, both within ...
Posted by Michael Wonder on 06 Mar 2017
NICE publishes draft guidance on the use of etelcalcetide for secondary hyperparathyroidism
3 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of etelcalcetide hydrochloride ...
Posted by Michael Wonder on 06 Mar 2017
Drug pricing report shows scope for more savings
6 March 2017 - The savings to the taxpayer in reducing the cost to Government of prescribed pharmaceuticals has been ...
Posted by Michael Wonder on 06 Mar 2017
Response to the Grattan Institute Report on medicine prices
6 March 2017 - Medicines Australia does not accept the findings of this latest inaccurate, selective and misleading Grattan Report ...
Posted by Michael Wonder on 06 Mar 2017
Chronic obstructive pulmonary disorder review - stakeholder forum
6 March 2017 - A stakeholder forum will be held for the post-market review of chronic obstructive pulmonary disorder medicines on ...
Posted by Michael Wonder on 05 Mar 2017
Australians paying four times above international prices for drugs
5 March 2017 - Yet another report from the Grattan Institute on the prices of off-patent medicines in the PBS; ...
Posted by Michael Wonder on 04 Mar 2017
Public Summary Documents - PBAC November 2016 meeting
3 March 2017 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the PBAC November 2016 ...